Zhejiang Huahai Pharmaceutical(600521.SH): Adenosine Cobalamin Capsules obtained the drug registration certificate
Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company recently received the Drug Registration Certificate for Adenosine Cobalamin Capsules approved and issued by the National Medical Products Administration. Adenosine Cobalamin Capsules are indicated for megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve paralysis; they can also be used as adjunctive treatment for nutritional disorders and leukopenia caused by radiation and drugs.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company recently received the Drug Registration Certificate for Adenosine Cobalamin Capsules approved and issued by the National Medical Products Administration. Adenosine Cobalamin Capsules are indicated for megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve paralysis; they can also be used as adjunctive treatment for nutritional disorders and leukopenia caused by radiation and drugs.
Related Articles
YUM CHINA (09987) repurchased 23,400 shares on October 16 for HK$8.289 million.
HANSOH PHARMA(03692): Enters into a Strategic Collaboration and License Agreement with Roche
TCL ELECTRONICS (01070) expects adjusted net profit attributable to parent for the first three quarters to increase by approximately 45% to 55% year-on-year.
YUM CHINA (09987) repurchased 23,400 shares on October 16 for HK$8.289 million.
HANSOH PHARMA(03692): Enters into a Strategic Collaboration and License Agreement with Roche
TCL ELECTRONICS (01070) expects adjusted net profit attributable to parent for the first three quarters to increase by approximately 45% to 55% year-on-year.
